Tonix Pharmaceuticals announced that it will acquire the US rights to Tosymra sumatriptan nasal spray from Upsher-Smith along with Zembrace SymTouch sumatriptan injection, both for the treatment of migraines. Dr. Reddy’s subsidiary Promius Pharma submitted an NDA for Tosymra in April 2018, and the FDA approved the product in January 2019. Upsher-Smith acquired the US rights to Tosymra in June 2019 from Dr. Reddy’s and launched the nasal spray in the US in October of that year.
Tonix CEO Seth Lederman commented, “Approximately 16% of Americans suffer from migraines, which represents about 40 million patients in the US. Sumatriptan remains the acute migraine ‘gold standard’ treatment for many patients and continues to represent the largest segment of the market in terms of unit sales. With migraine pain relief possible in as few as ten minutes for some patients and convenient administration, we believe both Zembrace SymTouch and Tosymra are well-suited to address the unmet needs of patients using traditional or emerging oral acute migraine medications, particularly for rapid-onset treatment.”
Lederman added, “In addition, these products align strongly with our TNX-1900 intranasal potentiated oxytocin product candidate, in clinical development for the prevention of chronic migraine. This is an important step in the evolution of Tonix into a fully integrated pharmaceutical company.”
Read the Tonix Pharmaceuticals press release.
